Zogenix, Inc. (NASDAQ: ZGNX) Receives Patent for ZX008 in the Treatment of Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX) has been issued a patent by the U.S. Patent Office for its drug candidate ZX008. The award of this patent, according to the company, marks the first time a patent has been issued covering a fenfluramine treatment of Dravet Syndrome and the seizures associated with it (http://dtn.fm/v69uD). The patent is seen by the company as offering protection of associated claims through 2033. “This represents the first issued patent covering the treatment of seizures associated with Dravet Syndrome using fenfluramine as an adjunctive therapy, and it is an important milestone for our ZX008 development program,” Stephen J.…